Compare Gilead Sciences, Inc. (GILD) vs Motorola Solutions Inc (MSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Motorola Solutions Inc — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.09B), while Motorola Solutions Inc trades at $446.82 (market cap $74.20B). The key difference: Gilead Sciences, Inc. is far larger — about 2.5× Motorola Solutions Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Motorola Solutions Inc for 100 Days on average.
| GILD | MSI | |
|---|---|---|
Market Cap | $182.09B | $74.20B |
Volume | 4,960,247 | 720,826 |
Sector | Health | Technology |
52-Week High | $155.80 | $491.24 |
52-Week Low | $116.74 | $363.83 |
Typical Hold Time | 111 Days | 100 Days |
Enterprise Value | $205.15B | $83.10B |
Dividend Yield | 2.23% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
Motorola Solutions (MSI) trades at $447.12, down 2.02% today, amid a bearish technical signal. The company maintains strong fundamentals with Q2 2026 EPS of $4.41 beating expectations and record backlog of $15.6 billion. Recent acquisitions including D-Fend Solutions for $1.5 billion expand its counter-drone security capabilities, while new contracts with Louisiana and the US Navy demonstrate ongoing demand.
MSI presents a compelling growth story with robust earnings momentum and strategic expansion, though elevated valuation ratios and significant capital expenditures pose risks. Analyst consensus remains bullish with a $525.86 price target, representing 17.6% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →
